2024 Watch List

Are we happy, you betcha! We just got back from St Croix where the team from the Beverage Stock Review visited the Mutiny Island Vodka...

Research Report Archive Reports from Robert LeBoyer at Noble Capital. Jeffrey Kraws and Karen Goldfarb at Crystal Research. Jason Kolbert at Dawson James Securities. Vernon...

Still our favorite biotech microcap, still our favorite management team, and our favorite risk to reward idea with a $4 million market cap, addressing...

Sanofi (SNY) Announces Partnership - $500 Million Upfront, plus $700 million in Milestones with NovaVax (NVAX). And some investors say Covid is gone -...

GeoVax (GOVX), Sees a Little Volume. Normally, we get a little nervous when one of the companies we follow, shows a spike in either...

Three Years Since we Last Added Citius (CTXR) to the Watch List, and it Looks Better Than Ever! We're adding Citius Pharma to the Watch...

CRANFORD, N.J., April 26, 2024 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class...

GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System Manufacturing Process for Phase 3 and Commercial Production Being Developed for GeoVax MVA-Based Vaccines ATLANTA, GA,...

Chief Scientific Officer, Mark Newman, PhD, will present data on GEO-CM04S1, the Company’s next-generation non-MRNA Covid-19 vaccine candidate on Thursday, April 4, 2024, 12:00...

Taking advantage of post reverse-split investor pessimism, is a VALID investing technique. Altamira is developing and supplying peptide-based nanoparticle technologies for efficient RNA delivery to...